QGEN - Qiagen N.V.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N. V. ("Qiagen" or the "Company") (NYSE: QGEN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface. “Researchers today are navigating growing scientific complexity, increasing volumes of data and expanding workflow choices,”.
TSM, QGEN and AG recently raised dividends as inflation, rising Treasury yields and oil prices fuel market volatility and economic concerns.
Qiagen shares dropped more than 10% after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER -- erasing hundreds of millions in market capitalization in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders of Qiagen N.V.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate to achieve “be.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
VENLO, Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery. The integration is designed to help pharmaceutical and biot.
Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Qiagen (QGEN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Qiagen and would like to discuss your legal rights, call Bragar Eagel and Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Qiagen (QGEN) To Contact Him Directly To Discuss Their Options
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
Qiagen's CEO and CFO signed SEC filings and personally delivered the guidance that was slashed within weeks -- investors who lost money may have legal claims against the individuals who controlled the company's public statements Qiagen's CEO and CFO signed SEC filings and personally delivered the guidance that was slashed within weeks -- investors who lost money may have legal claims against the individuals who controlled the company's public statements
Qiagen's forward-looking non-GAAP guidance lacked required GAAP reconciliations under SEC Regulation S-K Item 10(e) -- institutional investors who relied on these figures for portfolio allocation decisions may have been deprived of material information. NEW YORK, May 13, 2026 /PRNewswire/ -- Qiagen N.V.
Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders. The Annual General Meeting, to be held on June 24, 2026, in Venlo, the Netherlands, will include proposals to elect Robert McMahon as a new member of.
Examine Qiagen's (QGEN) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.